[뉴욕=뉴스핌]Correspondent Kim Geun-cheol = The European Medicines Agency (EMA) recommended conditional emergency use approval for the Corona 19 vaccine jointly developed by AstraZeneca and Oxford University in the UK on the 29th (local time).
As a result of reviewing clinical trials of the AstraZeneca Corona 19 vaccine conducted in the UK, Brazil, and South Africa on the same day, EMA recommended this urgent approval, saying that the vaccine has been shown to be safe and effective in preventing Corona 19 in people over the age of 18.
Accordingly, the European Commission (EU) is expected to decide the approval of emergency use sooner or later, and vaccination will begin in earnest in EU countries. In this case, AstraZeneca will be the third Corona 19 vaccine approved by the EU Commission for emergency use after Pfizer and Moder’s vaccine.
EMA said that the AstraZeneca vaccine requires two doses, and the interval is between 4 and 12 weeks.
However, EMA said that there is not yet sufficient results to determine how effective it is in the age group over 55, and that additional protective measures are expected for these age groups, and it is not clear about the extent of that.
Most of the participants in the AstraZeneca Corona 19 vaccine test consisted of 18 to 55 years old. Due to this, claims have been raised that question the safety and efficacy of vaccination for the elderly.
In particular, the immunization committee under the Robert Koch Institute (RKI), a health agency of the German Ministry of Health, issued an initial recommendation on the previous day, saying, “Astrezeneca vaccine should be vaccinated only for those aged 18-64.”
Meanwhile, World Health Organization (WHO) chief scientist Dr. Sumya Swaminatan said he hopes the AstraZeneca vaccine will be added to the WHO’s urgent use vaccine list within the next two weeks.
 |
| AstraZeneca Corona 19 Vaccine [사진=로이터 뉴스핌] |